StockData
Veracyte, Inc. logo

Veracyte, Inc. (VCYT) stock

VCYTNasdaqServices-Medical LaboratoriesFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 16/3034% below fair value
$25.57+1.34 (+5.53%)

Close on Nov 18, 2026Market cap $2.06BP/E 18.3Yield –

Veracyte pe ratio

The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.

Veracyte's pe ratio was 17.9× on Nov 11, 2026, against 124.6× a year earlier.

PE Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 202617.9×−92.9
2025Dec 31, 2025110.8×–

More Veracyte figures

See a number that looks wrong?